NCT03118024

Brief Summary

By comparison of two different protocols with diverse fluid/ catecholamine administration limits (fluid restriction vs. catecholamine restriction with target systolic blood pressure \> 100 mmHg) the investigators would like to reveal the impact of intraoperative blood pressure management on the survival rate of free deep inferior epigastric artery flaps for breast reconstruction.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Mar 2017

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 13, 2017

Completed
12 days until next milestone

First Submitted

Initial submission to the registry

March 25, 2017

Completed
24 days until next milestone

First Posted

Study publicly available on registry

April 18, 2017

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2019

Completed
Last Updated

April 18, 2017

Status Verified

April 1, 2017

Enrollment Period

2 years

First QC Date

March 25, 2017

Last Update Submit

April 12, 2017

Conditions

Keywords

deep inferior epigastric perforator flapfluid restrictioncatecholamine restriction

Outcome Measures

Primary Outcomes (1)

  • Free flap survival rate

    Rates of (partial) flap loss in each study arm

    5 days postoperatively

Secondary Outcomes (1)

  • Period of hospitalization

    up to 14 days

Study Arms (2)

Fluid restriction

ACTIVE COMPARATOR

Crystalloid fluid max. 2.0 ml/kg/h, no administration of colloids, noradrenaline max. 0.15 µg/kg/min

Drug: Crystalloid Solutions

Catecholamine restriction

ACTIVE COMPARATOR

Noradrenaline max. 0.04 µg/kg/min, fluids max. 8.0 ml/kg/h

Drug: Catecholamines

Interventions

crystalloid restrictive anesthesia protocol

Fluid restriction

catecholamine restrictive anesthesia protocol

Also known as: Norephinephrine
Catecholamine restriction

Eligibility Criteria

Age18 Years - 80 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Informed consent for study participation
  • Every patient undergoing breast reconstruction (primary and secondary reconstruction) with deep inferior epigastric perforator flap at our hospital is offered to participate in the study

You may not qualify if:

  • No informed consent for study participation
  • Patients with a high thromboembolic risk profile
  • During pregnancy and breastfeeding
  • Minors
  • Patients with a health care proxy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University hospital of Regensburg

Regensburg, 93053, Germany

RECRUITING

Related Publications (2)

  • Eley KA, Young JD, Watt-Smith SR. Epinephrine, norepinephrine, dobutamine, and dopexamine effects on free flap skin blood flow. Plast Reconstr Surg. 2012 Sep;130(3):564-570. doi: 10.1097/PRS.0b013e31825dbf73.

    PMID: 22929242BACKGROUND
  • Motakef S, Mountziaris PM, Ismail IK, Agag RL, Patel A. Emerging paradigms in perioperative management for microsurgical free tissue transfer: review of the literature and evidence-based guidelines. Plast Reconstr Surg. 2015 Jan;135(1):290-299. doi: 10.1097/PRS.0000000000000839.

    PMID: 25539313BACKGROUND

MeSH Terms

Interventions

Crystalloid SolutionsCatecholamines

Intervention Hierarchy (Ancestors)

Isotonic SolutionsSolutionsPharmaceutical PreparationsAminesOrganic ChemicalsCatecholsPhenolsBenzene DerivativesHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbons

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

March 25, 2017

First Posted

April 18, 2017

Study Start

March 13, 2017

Primary Completion

March 1, 2019

Study Completion

March 1, 2019

Last Updated

April 18, 2017

Record last verified: 2017-04

Data Sharing

IPD Sharing
Will not share

Locations